Immunomodulation following chemotherapy

Breast Cancer Research and Treatment

Volumn 38, Issue 1, 1996, Pages 41-48

  Obadina, M ^a   Verma, U ^a   Hawkins, M ^a   Mazumder, A ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Bone marrow transplant; Chemotherapy; Graft versus host disease; Graft versus leukemia effect; Immunotherapy

Indexed keywords

CYCLOSPORIN A; INTERFERON; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CELL STIMULATION; CONFERENCE PAPER; CYTOTOXICITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; MELANOMA B16; MOUSE; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL;

ANIMALS; BONE MARROW TRANSPLANTATION; CYCLOSPORINE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERONS; INTERLEUKIN-2; NEOPLASMS;

EID: 0030048870     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01803782     Document Type: Conference Paper

References (44)

1. Rosenberg SA: The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180-199, 1992
2. Glazier AD, Tutschka PJ, Farmer ER, Santos GW: Graft-versus-host disease in cyclosporine A-treated rats following syngeneic and autologous bone marrow reconstitution. J Exp Med 158:1-8, 1983
3. Noga SJ, Horwitz L, Kim H, Laulis MK, Hess AD: Interferon-γ potentiates the antitumor effect of cyclosporine-induced autoimmunity. J Hematotherapy 1:75-84, 1992
4. Gastl G, Marth C, Leiter E, Gattringer C, Mayer I, Daxenbichler G, Flener R, Huber C: Effects of human recombinant α arg-interferon and γ-interferon on human breast cancer cell lines: Dissociation of antiproliferative activity and induction of HLA-DR antigen expression. Cancer Res 45:2957-2961, 1985
5. Linch DC, Brunett AK: Clinical studies of ABMT in acute myeloid leukemia. Clin Hematol 15:167, 1986
6. Butturini A, Bortin MM, Gale RP: Graft versus leukemia following bone marrow transplantation. Bone Marrow Transplant 2:233-242, 1987
7. Geller RB, Esa AH, Beschorner WE, Frondoza CG, Santos GW, Hess AD: Successful in vitro graft-versus-tumor effect against an Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 74:1165-1171, 1989
8. Charak BS, Brynes RK, Groshen S, Chen SC, Mazumder A: Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 76:2187-2190, 1990
9. Ackerstein A, Kedar E, Slavin S: Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematological disorders. Blood 78:1212-1215, 1991
10. Klingemann HG, Grigg AP, Wilkie-Boyd K, Barnett MJ, Eaves AC, Reece DE, Sheperd JD, Philips GL: Treatment with recombinant interferon (α-2b) early after bone marrow transplantation in patients at high risk of relapse. Blood 78:3306-3311, 1991
11. Charak BS, Agah R, Mazumder A: Synergism of interleukin-2 and cyclosporine A in induction of a graft versus tumor effect without graft versus host disease after syngeneic bone marrow transplantation. Blood 80:179-184, 1992
12. Charak BS, Brynes RK, Katsuda S, Groshen S, Chen SC, Mazumder A: Induction of graft versus leukemia effect in bone marrow transplantation: Dosage and time schedule dependency of interleukin 2 therapy. Cancer Res 51:2015-2020, 1991
13. Charak BS, Sadowski RM, Mazumder A: Antitumor effect of interferon plus cyclosporine A for disseminated melanoma. Cancer Res 52:6482-6486, 1992
14. Charak BS, Agah R, Mazumder A: Granulocyte-macrophage colony stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow transplantation. Blood 81:3474-3479, 1993
15. Verma UN, Charak BS, Rajgopal C, Mazumder A: Interleukin-2 in bone marrow transplantation. In: Buccner D (ed) Technical and Biological Components of Marrow Transplantation. Kluwer, Boston, 1995.
16. Kennedy MJ, Vogelsang GB, Beveridge RA, Farmer ER, Altomonte V, Huelskamp AM, Davidson NE: Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 11:478-484, 1993
17. Hamon MD, Prentice HG, Gottlieb DJ, Macdonald ID, Cunningham JM, Smith OP, Gilmore M, Gandhi L, Collis C: Preliminary report. Immunotherapy with interleukin 2 after ABMT in AML. Bone Marrow Transplant 11:399-401, 1993
18. Soiffer RJ, Murray C, Cochran K: Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 79:517-526, 1992
19. Falkson C, Falkson G, Falkson H: Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9:1403-1408, 1991
20. Ujiie T: Increased sensitivity of tumor cells to immune defense cells following treatment with anti-neoplastic agents in vitro. Jpn J Exp Med 59:17-26, 1989
21. Kennedy MJ, Jones RJ: Autologous graft-versus-host disease: Immunotherapy of breast cancer after bone marrow transplantation. Breast Can Res Treat 26: s31-s40, 1993
22. Rosenberg SA, Grimm EA, McGrogan M, et al: Biological activity of recombinant human interleukin-2 produced in Escherichia coli. The Sciences (Wash DC) 223:1412-1417, 1984
23. Richards JM, Mehta N, Ramming K, Skosey P: Sequential chemoimmunotherapy in the treatment of metastatic melanoma, J Clin Oncol 10:1338-1343, 1992
24. Rosenberg SA, Lotze MT, Yang JC, et al: Combination therapy with interleukin-2 and alpha interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863-1874, 1989
25. Verma UN, Bagg A, Brown E, Mazumder A: Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors. Bone Marrow Transplant 13:115-123, 1994
26. Kennedy MJ, Vogelsang GB, Jones RJ, Farmer ER, Hess AD, Altomonte V, Huelskamp AM, Davidson NE: Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 12:249-257, 1994
27. Verma UN, Areman E, Dickerson SA, Kotula PL, Sacher R, Mazumder A: Interleukin-2 activation of chemotherapy and growth factor mobilized peripheral blood stem cells for generation of cytotoxic effectors [abstract]. Proc Am Soc Hematol, 1994
28. Hess AD, Horwitz L, Beschorner WE, Santos GW: Development of graft-vs-host disease-like syndrome in cyclosporine treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T-lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J Exp Med 161:718-730, 1985
29. Agah R, Malloy B, Kerner M, Mazumder A: Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs. tumor effector in transplantation. J Immunol 143:3093-3099, 1989
30. Agah R, Malloy B, Kerner M, Girgis E, Bean P, Twomey P, Mazumder A: Potent graft antitumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin-2 activated syngeneic bone marrow in mice. Cancer Res 49:5959, 1989
31. Papa ML, Yang YC, Vetto JT, Shiloni E, Eisenthal A, Rosenberg SA: Combined effects of chemotherapy and interleukin-2 in the therapy of mice with advanced pulmonary tumors. Cancer Res 48:122-129, 1988
32. North RJ: Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor cells. J Exp Med 155:1063-1074, 1982
33. Nagarkatti M, Kaplan AM: The role of suppressor T-cells in BCNU-mediated rejection of a syngeneic tumor. J Immunol 135:1510-1517, 1985
34. Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC: Effectiveness and tolerability of low dose cyclophosphamide and low dose intravenous interleukin-2 disseminated melanoma. J Clin Oncol 6:409-424, 1988
35. Rosenberg SA: Immunotherapy of cancer using interleukin-2. Current status and future prospects. Immunol Today 9:58-62, 1988
36. Lotze MT, Custer MC, Sharrow LA, et al: In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 positive cells and circulating soluble interleukin-2 receptors following interlcukin-2 administration. Cancer Res 47:2188-2195, 1987
37. Waldmann TA: The multi-subunit interleukin-2 receptor. Ann Rev Biochem 58:875-911, 1989
38. Smith KA. The interleukin-2 receptor. In: Dixon FJ (ed) Advances in Immunology. Academic Press, San Diego, 1988, pp 165-179
39. Mouawad R, Ichen M, Rixe O, Benhammouda A, Vuillemin E, Weil M, Khayat D, Soubrane C: Study of IL-2 receptor expression after chemoimmunotherapy in patients treated for metastatic malignant melanoma. Clin Exp Immunol 97:342-346, 1994
40. Khayat D, Borel C, Tourani A, Benhammouda A, Antoine E, Rixe O, Vuillemin E, Bazex PA, Thill L, Franks R, Auclerc G, Soubrane C, Banzet P, Weil M: Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 11:2173-2180, 1993
41. Demchak PA, Mier JW, Robert NJ, et al: Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma. A pilot study. J Clin Oncol 9:1821-1830, 1991
42. Legha S, Plager C, Ring S, et al: A phase II study of biochemotherapy using interleukin 2 + interferon alpha-2a in combination with cisplatin, vinblastine and DTIC in patients with metastatic melanoma. Proc Am Soc Clin Oncol 11:343, 1992
43. Hamblin TJ, Davies B, Sadullah S, et al: A phase II study of the treatment of metastatic malignant melanoma with a combination of dacarbazine, cisplatin, interleukin 2 and alpha-interferon. Proc Am Soc Clin Oncol 10:294, 1991
44. Blair S, Flaherty L, Valdivieso M, et al: Comparison of high dose interleukin 2 with combined chemotherapy low-dose IL-2 in metastatic malignant melanoma. Proc Am Soc Clin Oncol 10:294, 1991